spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Erythromycin 

 HSMN NewsFeed - 29 Oct 2024
Protega Pharmaceuticals Receives FDA Approval for ROXYBOND(TM) (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Aug 2023
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Mar 2019
ANI Pharmaceuticals Announces Two Generic Product Launches
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 7 May 2018
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
Biopharmaceuticals Generics Acquisitions
 HSMN NewsFeed - 21 Jul 2017
Teligent, Inc. Announces FDA Approval Of Erythromycin Topical Gel USP, 2%
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2014
FDA Approves Boehringer Ingelheim's OFEV(R) (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Dec 2013
VIVUS Announces License and Commercialization Agreement With Sanofi for Avanafil in Africa, Middle East, Turkey and CIS/Russia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Jun 2013
VIVUS Announces SPEDRA (avanafil) Approval in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Sep 2012
Cialis(R) (tadalafil) Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 7 Feb 2012
New Study Evaluates Cialis(R) in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 1 Feb 2012
FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jan 2012
New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 7 Oct 2011
Cialis(R) for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) and Men With Both Erectile Dysfunction (ED) and Signs and Symptoms of BPH
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Feb 2011
Covidien Receives FDA Approval for Fentanyl Transdermal System Patch
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2010
Akorn Announces FDA Approval to Re-Launch Erythromycin Ophthalmic Ointment USP 3.5 g
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2010
Teva UK Limited Launches Lercanidipine Hydrochloride Film-Coated Tablets
Biopharmaceuticals Generics
 HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Dec 2007
New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Biopharmaceuticals
 HSMN NewsFeed - 13 Aug 2007
InSite Vision Announces U.S. Launch of AzaSite(TM) for Ocular Infections
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Aug 2007
Inspire Pharmaceuticals Launches AzaSite(TM) in the United States for Ocular Infections
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 May 2007
Abraxis BioScience Receives FDA Approvals for Clindamycin Injection, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 27 Apr 2007
Inspire Announces FDA Approval Of AzaSite(TM)
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Senetek Initiates Clinical Trials of Pyratine 6 for Acne Rosacea
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 10 Apr 2007
Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 16 Feb 2007
Inspire Licenses AzaSite(TM) For Ocular Infections
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 16 Feb 2007
InSite Vision Announces License Agreement With Inspire Pharmaceuticals
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 20 Dec 2006
Kosan Announces License of Motilin Agonist Program to Pfizer
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2006
Newly-Published Data Showed LEVITRA(R) Treated Erectile Dysfunction Effectively at First Dose In Men With Certain Associated Cardiovascular Conditions
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 22

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 22 additional stories matching:
Erythromycin
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!